Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods

Background: The demand for new anti-TB drugs is high, but development programmes are long and costly. Consequently there is a need for new strategies capable of accelerating this process. Objectives: To explore the power to find statistically significant drug effects using a model-based pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Svensson, Robin J., Gillespie, Stephen H., Simonsson, Ulrika S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890728/
https://www.ncbi.nlm.nih.gov/pubmed/28520930
http://dx.doi.org/10.1093/jac/dkx129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890728/
https://www.ncbi.nlm.nih.gov/pubmed/28520930
http://dx.doi.org/10.1093/jac/dkx129

Ejemplares similares